Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Liver specific magnetic resonance imaging contrast medium for evaluation of focal liver lesions - Initial experience at a service hospital.

George RA, Godara SC, Srinivas V.

Med J Armed Forces India. 2012 Oct;68(4):350-5. doi: 10.1016/j.mjafi.2012.07.001. Epub 2012 Aug 20.

2.

Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.

Schneider G, Maas R, Schultze Kool L, Rummeny E, Gehl HB, Lodemann KP, Kirchin MA.

Invest Radiol. 2003 Feb;38(2):85-94.

PMID:
12544071
3.

MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.

Grazioli L, Morana G, Kirchin MA, Caccia P, Romanini L, Bondioni MP, Procacci C, Chiesa A.

J Magn Reson Imaging. 2003 May;17(5):593-602.

PMID:
12720270
4.

Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.

Petersein J, Spinazzi A, Giovagnoni A, Soyer P, Terrier F, Lencioni R, Bartolozzi C, Grazioli L, Chiesa A, Manfredi R, Marano P, Van Persijn Van Meerten EL, Bloem JL, Petre C, Marchal G, Greco A, McNamara MT, Heuck A, Reiser M, Laniado M, Claussen C, Daldrup HE, Rummeny E, Kirchin MA, Pirovano G, Hamm B.

Radiology. 2000 Jun;215(3):727-36.

PMID:
10831691
5.

Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.

Grazioli L, Morana G, Caudana R, Benetti A, Portolani N, Talamini G, Colombari R, Pirovano G, Kirchin MA, Spinazzi A.

Invest Radiol. 2000 Jan;35(1):25-34.

PMID:
10639033
6.

[Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].

Zhang HM, Ouyang H, Zhou CW.

Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):111-5. Chinese.

PMID:
16750014
7.

Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient.

Wersebe A, Wiskirchen J, Decker U, Schick F, Dietz K, Müller-Schimpfle M, Claussen CD, Pereira PL.

Invest Radiol. 2006 Mar;41(3):264-71.

PMID:
16481909
8.

Detectability of small liver metastases with gadolinium BOPTA.

Runge VM, Lee C, Williams NM.

Invest Radiol. 1997 Sep;32(9):557-65.

PMID:
9291044
9.

Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions.

Fu GL, Du Y, Zee CS, Yang HF, Li Y, Duan RG, Zeng NL, Xiao DM.

J Comput Assist Tomogr. 2012 Jan-Feb;36(1):14-9. doi: 10.1097/RCT.0b013e31823dc139.

PMID:
22261765
10.

Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.

Marin D, Iannaccone R, Catalano C, Passariello R.

J Magn Reson Imaging. 2006 Sep;24(3):690-4.

PMID:
16878304
11.

Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.

del Frate C, Bazzocchi M, Mortele KJ, Zuiani C, Londero V, Como G, Zanardi R, Ros PR.

Radiology. 2002 Dec;225(3):766-72.

PMID:
12461259
12.

Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.

Schneider G, Altmeyer K, Kirchin MA, Seidel R, Grazioli L, Morana G, Saini S.

Invest Radiol. 2007 Feb;42(2):105-15.

PMID:
17220728
13.

Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.

Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB.

Eur J Radiol. 2008 Apr;66(1):65-74. Epub 2007 Jun 6.

PMID:
17555901
14.

Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.

Runge VM, Wells JW, Williams NM.

Invest Radiol. 1996 Dec;31(12):781-8.

PMID:
8970881
15.
16.

Off-site evaluation of liver lesion detection by Gd-BOPTA-enhanced MR imaging.

Gehl HB, Bourne M, Grazioli L, Möller A, Lodemann KP.

Eur Radiol. 2001;11(2):187-92.

PMID:
11218012
17.

Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.

Pastor CM, Planchamp C, Pochon S, Lorusso V, Montet X, Mayer J, Terrier F, Vallee JP.

Radiology. 2003 Oct;229(1):119-25. Epub 2003 Aug 27.

PMID:
12944603
18.

Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine.

Grazioli L, Bondioni MP, Faccioli N, Gambarini S, Tinti R, Schneider G, Kirchin M.

J Gastrointest Cancer. 2010 Dec;41(4):221-32. doi: 10.1007/s12029-010-9145-0.

PMID:
20405242
19.

Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Peña CS, Saini S, Baron RL, Hamm BA, Morana G, Caudana R, Giovagnoni A, Villa A, Carriero A, Mathieu D, Bourne MW, Kirchin MA, Pirovano G, Spinazzi A.

Korean J Radiol. 2001 Oct-Dec;2(4):210-5.

20.

Supplemental Content

Support Center